University Hospitals of Leicester NHS Trust

RS Oncology presents new drug in early clinical development for Mesothelioma and lung cancer patients

Retrieved on: 
Thursday, August 3, 2023

RS Oncology is bringing exciting new science to patients who will have the best chance of benefiting from new therapies.

Key Points: 
  • RS Oncology is bringing exciting new science to patients who will have the best chance of benefiting from new therapies.
  • PRX3 is a novel drug target with potential for treating patients with the asbestos related cancer, mesothelioma.
  • “PRX3 is a novel and interesting therapeutic drug target with potential for treating cancers, especially those with unmet need such as mesothelioma.
  • We await the first clinical results with interest.”
    For more information about MITOPE clinical trial visit Mesothelioma UK .

Caristo Diagnostics Piloting New Cardiac Disease Diagnostic Technology in UK NHS Hospitals

Retrieved on: 
Wednesday, July 12, 2023

OXFORD, England, July 12, 2023 /PRNewswire/ -- Caristo Diagnostics Limited, a global leader in cardiac and vascular disease diagnostics and risk prediction, announces today that it is deploying its latest CaRi-Heart® technology in National Health Service (NHS) hospitals as part of a new coronary artery disease (CAD) management pathway pilot.

Key Points: 
  • OXFORD, England, July 12, 2023 /PRNewswire/ -- Caristo Diagnostics Limited , a global leader in cardiac and vascular disease diagnostics and risk prediction, announces today that it is deploying its latest CaRi-Heart® technology in National Health Service (NHS) hospitals as part of a new coronary artery disease (CAD) management pathway pilot.
  • The new pilot supported by NHS England will involve five NHS trusts, including University Hospitals of Leicester NHS Trust, Liverpool Heart and Chest Hospitals NHS Foundation Trust, Milton Keynes University Hospital NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, and Royal Wolverhampton NHS Trust.
  • The latest CaRi-Heart platform was released recently for UK and EU markets and can detect both coronary inflammation and atherosclerosis (plaque), based on routine cardiac CT scans.
  • "Caristo and our clinical partners are excited about this ground-breaking clinical initiative supported by NHS England", said Frank Cheng, Caristo Diagnostics CEO, "We anticipate that this real-world implementation will pave the way for the CaRi-Heart technology to be broadly adopted both across the NHS and around the world".

Caristo Diagnostics Piloting New Cardiac Disease Diagnostic Technology in UK NHS Hospitals

Retrieved on: 
Wednesday, July 12, 2023

OXFORD, England, July 12, 2023 /PRNewswire/ -- Caristo Diagnostics Limited, a global leader in cardiac and vascular disease diagnostics and risk prediction, announces today that it is deploying its latest CaRi-Heart® technology in National Health Service (NHS) hospitals as part of a new coronary artery disease (CAD) management pathway pilot.

Key Points: 
  • OXFORD, England, July 12, 2023 /PRNewswire/ -- Caristo Diagnostics Limited , a global leader in cardiac and vascular disease diagnostics and risk prediction, announces today that it is deploying its latest CaRi-Heart® technology in National Health Service (NHS) hospitals as part of a new coronary artery disease (CAD) management pathway pilot.
  • The new pilot supported by NHS England will involve five NHS trusts, including University Hospitals of Leicester NHS Trust, Liverpool Heart and Chest Hospitals NHS Foundation Trust, Milton Keynes University Hospital NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, and Royal Wolverhampton NHS Trust.
  • The latest CaRi-Heart platform was released recently for UK and EU markets and can detect both coronary inflammation and atherosclerosis (plaque), based on routine cardiac CT scans.
  • "Caristo and our clinical partners are excited about this ground-breaking clinical initiative supported by NHS England", said Frank Cheng, Caristo Diagnostics CEO, "We anticipate that this real-world implementation will pave the way for the CaRi-Heart technology to be broadly adopted both across the NHS and around the world".

AliveCor joins forces with Dignio to streamline the transfer of personal electrocardiogram data between patient and clinician

Retrieved on: 
Wednesday, September 28, 2022

MOUNTAIN VIEW, Calif., Sept. 28, 2022 /PRNewswire/ -- AliveCor , the leading innovator in personal electrocardiogram (ECG) technology, today announced a new integration partnership with health tech specialist Dignio.

Key Points: 
  • MOUNTAIN VIEW, Calif., Sept. 28, 2022 /PRNewswire/ -- AliveCor , the leading innovator in personal electrocardiogram (ECG) technology, today announced a new integration partnership with health tech specialist Dignio.
  • The app connects to several devices, including blood pressure monitors and pulse oximeters, and now it also connects to KardiaMobile.
  • The method for transferring remotely recorded ECG data between patients and clinicians can be challenging.
  • Its 'My Dignio' and 'Dignio Care' smartphone and tablet apps connect directly to its 'Dignio Prevent' data platform, which is used by clinicians to assess patients remotely in real-time.

Imspex Diagnostics announces BreathSpec® Instrument

Retrieved on: 
Tuesday, August 9, 2022

ABERCYNON, Wales, Aug. 9, 2022 /PRNewswire/ -- Imspex Diagnostics Ltd today announced that it has received CE mark for its BreathSpec® instrument for the detection of COVID-19 using non-invasive breath testing and analysis having met the requirements of the European In-Vitro Diagnostics Directive (98/79/EC). 

Key Points: 
  • Breathspec is Imspex's proprietary breath analyzer using a unique combination of gas chromatography (GC) and ion mobility spectrometry (IMS) technologies to deliver fast and accurate results.
  • "This is a global first for breath-based Covid-19 testing and a major step towards our mission to bring breath-based testing into the mainstream" said John McKinley, CEO of Imspex Diagnostics.
  • Imspex is a leader in Breathomics, the non-invasive way to address major healthcare challenges.
  • Breath collection and analysis is carried out using Imspex's lead instrument, BreathSpec.

NuvoAir Launches Remote Asthma Service to Support NHS with Faster Diagnosis and Treatment

Retrieved on: 
Wednesday, May 25, 2022

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220523005860/en/
    Since 2017, NuvoAir has worked with over 40 NHS trusts, enabling NHS services to manage nearly 5,000 respiratory patients.
  • May is Asthma Awareness Month and efforts are underway to educate the public on the status of asthma in the UK, where asthma deaths are amongst the worst in Europe.
  • The NuvoAir Asthma Service will potentially improve access to this aspect of asthma care for people with asthma, leading to fewer asthma symptoms and attacks, says Professor Peter Bradding from University Hospitals of Leicester NHS Trust.
  • NuvoAir Founder and CEO, Lorenzo Consoli shares, We are excited to partner with the NHS and forward-looking clinicians to redesign new care pathways for people with asthma.

Deenova Launches First Ever, Pay-Per-Dose Unit Dose Pharmacy Automation Service in England

Retrieved on: 
Tuesday, May 3, 2022

Today, Deenova announced that it is launching its innovative Pay-Per-Dose unit dose pharmacy automation service to the UK market for the first time.

Key Points: 
  • Today, Deenova announced that it is launching its innovative Pay-Per-Dose unit dose pharmacy automation service to the UK market for the first time.
  • Deenova thus opens its market reach to short-term and easy-to-adopt contractual arrangements and flexibility in Englands Pharmacy Automation market.
  • The new pay-per-dose unit dose pharmacy automation is a full service, yet modular solution.
  • Deenova will officially launch its pay-per-dose unit dose pharmacy automation solution during the UK Clinical Pharmacy Congress at the lunch time symposia show, floor theatre, Friday 13 May at 1:00pm.

Leicester’s Hospitals Awards Deenova a Unit Dose Pharmacy Automation 15 Year Contract

Retrieved on: 
Monday, August 2, 2021

Deenova was selected by University Hospitals of Leicester NHS Trust as the best solution amongst 8 of Deenova 's competitors in United Kingdom and the United States of America.

Key Points: 
  • Deenova was selected by University Hospitals of Leicester NHS Trust as the best solution amongst 8 of Deenova 's competitors in United Kingdom and the United States of America.
  • Claire Ellwood, chief pharmacist at University Hospitals of Leicester NHS Trust , said: Were proud to be working with Deenova to deploy the first unit dose closed loop medicines management system in the UK.
  • After a successful pilot, we are pleased to start planning the roll out across our three hospitals.
  • University Hospitals of Leicester NHS Trust : Every day at Leicesters Hospitals we save lives, improve lives and usher in new life.